Charles River Laboratories International (NYSE:CRL) Posts Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Charles River Laboratories International (NYSE:CRL) released its earnings results on Wednesday. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16, Zacks reports. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter last year, the firm posted $2.46 earnings per share. The firm’s revenue was down 1.1% on a year-over-year basis. Charles River Laboratories International updated its FY 2025 guidance to 9.100-9.600 EPS and its FY25 guidance to $9.10-$9.60 EPS.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $165.00 on Thursday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a 12 month low of $150.79 and a 12 month high of $275.00. The stock has a market cap of $8.44 billion, a P/E ratio of 20.65, a P/E/G ratio of 5.91 and a beta of 1.37. The company has a 50 day moving average of $174.02 and a 200 day moving average of $188.99.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. UBS Group reiterated a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Morgan Stanley decreased their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Bank of America decreased their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $197.64.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).